Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Phase 2

Not yet recruiting

• Conditions: Hypophosphatemia; Kidney Transplantation
• Interventions: Drug: Dipyridamole 75 MG

• Registration Number: NCT06824454
• Lead Sponsor: Stanford University

Brief Summary

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-11
• Study First Submitted: 2025-02-07
• Study First Submitted QC: 2025-02-07
• Last Update Submitted: 2025-02-07
• Study First Posted: 2025-02-13
• Last Update Posted: 2025-02-13
• Study Start: 2025-03
• Primary Completion: 2026-03
• Study Completion: 2026-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Adult kidney transplant patients.
• No known contraindications to Dipyridamole

Exclusion Criteria

• Contraindications to Dipyridamole.
• Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
• Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment Group	Dipyridamole 75 MG	Participants receive Dipyridamole in addition to standard post-transplant care.

Primary Outcome Measures

Name	Time	Method
Change in Serum Phosphorus Levels After Dipyridamole Administration	Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio	This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.

Trial Locations

Locations (1)

Stanford University; 🇺🇸 Stanford, California, United States